公开(公告)号：US11066472B2

公开(公告)日：2021-07-20

申请号：US16230356

申请日：2018-12-21

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky

IPC: A61P9/10 ,  A61P3/06 ,  A61K39/395 ,  C07K16/28 ,  A61P9/04 ,  C12N15/113 ,  C07H21/02 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

公开(公告)号：US20210163601A1

公开(公告)日：2021-06-03

申请号：US16987237

申请日：2020-08-06

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky ,  Derek E. Piper ,  Fernando Garces ,  Jun Zhang ,  Yang Li ,  Brian Mingtung Chan

IPC: C07K16/28 ,  A61P9/10 ,  A61P9/04 ,  C12N15/113 ,  C07H21/02 ,  A61P3/06 ,  A61K39/395 ,  A61K45/06

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

公开(公告)号：US20190248902A1

公开(公告)日：2019-08-15

申请号：US16230356

申请日：2018-12-21

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky ,  Derek E. Piper ,  Fernando Garces ,  Jun Zhang ,  Yang Li ,  Brian Mingtung Chan

IPC: C07K16/28 ,  C07H21/02 ,  A61K39/395 ,  A61P9/10 ,  A61P9/04 ,  A61K45/06 ,  C12N15/113

CPC classification number: C07K16/2851 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61P9/04 ,  A61P9/10 ,  C07H21/02 ,  C07K14/705 ,  C07K16/28 ,  C07K2317/30 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/1138

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

公开(公告)号：US10358497B2

公开(公告)日：2019-07-23

申请号：US15279162

申请日：2016-09-28

Applicant: Amgen Inc

Inventor： Paul Nioi ,  Jun Zhang ,  Yang Li

IPC: C12N15/113 ,  C07H21/02 ,  A61P9/04 ,  A61P9/10 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

公开(公告)号：US20250051457A1

公开(公告)日：2025-02-13

申请号：US18770259

申请日：2024-07-11

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky ,  Derek E. Piper ,  Fernando Garces ,  Jun Zhang ,  Yang Li ,  Brian Mingtung Chan

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P3/06 ,  A61P9/04 ,  A61P9/10 ,  C07H21/02 ,  C07K14/705 ,  C12N15/113

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

公开(公告)号：US20170088620A1

公开(公告)日：2017-03-30

申请号：US15279162

申请日：2016-09-28

Applicant: Amgen Inc.

Inventor： Paul Nioi ,  Peter Coward ,  Christopher Murawsky ,  Derek E. Piper ,  Fernando Garces ,  Jun Zhang ,  Yang Li ,  Brian Mintung Chang

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2851 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61P9/04 ,  A61P9/10 ,  C07H21/02 ,  C07K14/705 ,  C07K16/28 ,  C07K2317/30 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/1138

Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.